40800-65-5

Basic information

• Product Name: Ethyl 4-amino-3-methylbenzoate
• Synonyms: AKOS BB-3095;ETHYL 4-AMINO-3-METHYLBENZOATE
• CAS NO: 40800-65-5
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.22
• Product Categories: pharmacetical
• Mol File: 40800-65-5.mol

Chemical Properties

• Boiling Point: 327.039 °C at 760 mmHg
• Flash Point: 177.203 °C
• Appearance: /
• Density: 1.104 g/cm³
• Vapor Pressure: 0.000207mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: Ethyl 4-amino-3-methylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-amino-3-methylbenzoate(40800-65-5)
• EPA Substance Registry System: Ethyl 4-amino-3-methylbenzoate(40800-65-5)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 40800-65-5(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 95, p. 588, 1973 DOI: 10.1021/ja00783a048Organic Syntheses, Coll. Vol. 6, p. 581, 1988

InChI:InChI=1/C10H13NO2/c1-3-13-10(12)8-4-5-9(11)7(2)6-8/h4-6H,3,11H2,1-2H3

Upstream product

• 3113-71-1 3-methyl-4-nitrobenzoic acid 
• 64-17-5 ethanol 
• 2486-70-6 4-amino 3-methylbenzoic acid 
• 30650-90-9 3-methyl-4-nitro-benzoic acid ethyl ester 

Downstream Products

• 70204-39-6 Essigsaeure-<4-acetamido-3-methyl-benzylester> 
• 808745-05-3 ethyl 4-acetamido-3-methylbenzoate 
• 192944-51-7 1H-indazole-5-carboxylic acid ethyl ester 
• 192944-50-6 ethyl 1-acetyl-1H-indazole-5-carboxylatee 
• 1314398-37-2 ethyl 1-methyl-1H-indazole-5-carboxylate 
• 1334405-45-6 ethyl 2-methyl-2H-indazole-5-carboxylate 
• 1092961-11-9 (1-methyl-1H-indazol-5-yl)methanol 
• 1189889-44-8 4-{[2-n-propyl-4-methyl-6-(1-methyl-d₃-benzoimidazol-2-yl)benzoimidazol-1-yl]methyl}biphenyl-2-carboxylic acid 
• 87-62-7 2,6-dimethylaniline 
• 808744-87-8 ethyl 1-[(3-chloro-1,1'-biphenyl-4-yl)methyl]-2,4-dimethyl-1H-benzimidazole-6-carboxylate 
• 808745-07-5 ethyl 4-(acetylamino)-3-amino-5-methylbenzoate 
• 808744-96-9 ethyl 2,4-dimethyl-1H-benzimidazole-6-carboxylate 

Relevant articles and documents

Deuterated methyl telmisartan as well as preparation method and application thereof

The invention belongs to the field of organic and pharmaceutical synthesis, and discloses deuterated methyl telmisartan as well as a preparation method and application thereof. The method adopts 3-methyl-4-nitrobenzoic acid as a raw material, adopts deute

Oxygen-Tolerant H2 Production by [FeFe]-H2ase Active Site Mimics Aided by Second Sphere Proton Shuttle

The instability of [FeFe]-H2ases and their biomimetics toward O2 renders them inefficient to implement in practical H2 generation (HER). Previous investigations on synthetic models as well as natural enzymes proved that re

THIAZOLIDINONE COMPOUNDS AND USE THEREOF

A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR

A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

Synthesis of symmetric diester-functionalised Troeger's base analogues

The yields of ester-functionalised Troeger's base analogues are dramatically improved by incorporating an electron-donating group on the aromatic ring and/or enhancing solubil- ity of the aniline unit. In addition to 2,8-diester compounds, 1,7-, 3,9- and 4,10-diester-functionalised Troeger's base analogues have been prepared for the first time.

Integrin antagonists

This invention relates to novel heterocycles which are useful as antagonists of the αvβ3 integrin, the α2bβ3 integrin, and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Integrin receptor antagonists

This invention relates to novel heterocycles including 3-?1-?3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the αv β3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Process for producing azasulfonium salts and rearrangement thereof to thio-ethers

Preparing ortho-substituted anilines by reacting an N-chloroaniline with a non-carbonylic di-hydrocarbon sulfide to form an azasulfonium chloride, reacting the azasulfonium chloride with a strong base to form an aniline substituted in the 2-position with a hydrocarbon-S-hydrocarbyl thio-ether group. The ortho-substituted thio-ether compounds can be reduced with a de-sulfurizing reducing agent such as Raney nickel or the like to form the ortho-alkylated aniline. The aniline may be an amino-pyridine. The azasulfonium salt and thio-ether intermediate products can be isolated and recovered. If desired, the thio-ether compounds can be reduced to form ortho-alkylated aniline products which are useful as intermediates for a wide variety of purposes, including their uses in making dyes, herbicides, and the like.